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Abstract
Continuous exposure to schistosome-infested water results in acute and chronic
morbidity in all ages. We analysed occurence of organomegaly via ultrasonogra-
phy and investigated a possible additive effect of dual-dose drug administration in
401 Schistosoma haematobium infected individuals from a highly endemic area in
Mali. Mean intensity of infection at baseline (22.0 eggs per 10 ml) was reduced to
0.22 eggs per 10 ml 9 weeks after treatment (both treatments combined). Odds of
persistent infection among those given dual-dose treatment was 41% of that in
people given single dose (b = 0.41; p = 0.05; 95% CI 0.17–1.00), but after two
years, 70.7% of the 157 participants, who completed the survey, were re-infected
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with no significant difference in prevalence and intensity of infection between
treatment groups. Resolution of organomegaly occurred in all age groups after
treatment. A novel association between Schistosoma haematobium infection and
moderate portal vein enlargement was found in 35% (n: 55). Severe portal vein
diameter enlargement was found in 3.2%. After two years, moderate hepatomegaly
was present in 50.6%, moderate splenomegaly in 45.6% and moderate portal vein
diameter enlargement in 19%. A subsequent dose of PZQ did not provide any
additional long-term advantages.
Keyword: Infectious disease
1. Introduction
A national control program to reduce the burden of schistosomiasis infections was
initiated in Mali in 1978, resulting in a national prevalence reduction from 58.9% to
26.8% of Schistosoma haematobium, the most prevalent schistosome species in the
country [1]. Within a few years, however, prevalence rebounded to pre-
intervention levels due to reinfection [1]. Programs focus on school-aged children,
even though nearly half of children aged 3 months–5 years have active infections
causing detrimental effects on health and development [2]. Young adults are also
not included in most programs. The WHO global target of eliminating NTDs aims
for a minimum of 75% coverage of preventive chemotherapy in pre-school and
school-age children by 2020 [3, 4].
S. haematobium infection causes morbidity in the urinary tract and genital organs
due to inflammation and granulomatous immunologic host responses to trapped
eggs [5]. Organ lesions are positively correlated with intensity of infection [6].
Indications of genital involvement associated with S. haematobium infection have
been shown in school aged girls [7] and untreated lesions may persist leading to
reproductive and sexually related illnesses in adults [8]. Of great concern in sub-
Saharan Africa is the fact, that individuals with genital schistosomiasis are at
increased risk of HIV-acquisition [8, 9]. Development of hepato-splenomegaly is
well known in S. japonicum and S. mansoni infections where congestive
splenomegaly develops from focal inflammatory lesions provoked by eggs and
dead worms resulting in necrosis, obstruction of vessels and scarring [10] but is not
generally accepted as a feature of S. haematobium infection.
S. haematobium lesions resolve within the first six months after treatment, but
frequently reappear within two years depending on the level of transmission [11,
12]. This has been ascribed to reinfection and a persistent low intensity infection
due to the survival of young parasites, as PZQ only kills adult schistosomes
[13, 14, 15, 16]. Various treatment strategies have been suggested to overcome the
issue of persisting exposure such as coordinating treatment with transmission
season [17] or repeating treatment when worm, that were immature at the first
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treatment round and thus not susceptible to PZQ, have matured [18]. PZQ has
previously been shown to eradicate up to 90% of worms and eggs, but the
reappearance of circulating anodic antigen (CAA) in serum as early as one week
post-treatment reveals greater residual infection than previously expected [19].
This study sought to investigate a hypothesized association of organomegaly
related to S. haematobium infection and to explore resolution after treatment in
randomized treatment with single-dose or dual-dose PZQ treatment.
2. Materials and methods
Data collection took place in the Segou region of Mali as part of a larger multi-
disciplinary study [20, 21]. The semi-arid savannah area is located 235 km from
the capital, Bamako. Approximately 50% of the population lives along the Niger
River. Water contact activities, such as farming, fishing, livestock keeping and
daily household activities place people at risk of schistosomiasis transmission. The
area is a known S. haematobium endemic area and malacological studies confirm
that S. mansoni vector snails are rare in the area (Personal communication). S.
haematobium is mainly found along rivers with no or very low prevalence of S.
mansoni, which is found mainly in irrigation areas [22]. Demographic numbering
of all houses and registration of all household members was performed by trained
demographers and randomization to treatment strategy was done by computerized
random selection balanced for sex and age [20, 21].
Participants enrolled in the study were between 2 and 65 years of age and had not
received any previous PZQ treatment. A total of 402 individuals were screened.
Sample size estimation was mainly based on comparing two proportions
(proportion still positive) after single or double treatment, assuming these
proportions to be 0.15 and 0.03, respectively, assuming that 80% of the participants
were positive and that 15% would be lost to follow-up. Using a significance level
of 0.05 and a power 90% showed that the sample size should be 175 in each group.
Since only 4 people over 40 years of age participated, we limited the analysis to
individuals between the ages of 2 and 40. One participant never provided urine.
The residual 212 females and 189 males donated samples and were randomized
into single-dose or dual-dose directly observed treatment (DOT) with PZQ 40 mg/
kg body weight. A second dose of PZQ was administered two weeks after the
primary treatment. The single-dose regimen was administered to 225/401 of
participants (56.1%, 123 females/102 males). The second PZQ dosing was
administered to 176/401 participants (43.9%, 89 females/87 males). All
participants, regardless of schistosomiasis status, were treated at baseline and
after two years follow-up to secure treatment of false negative individuals.
The following three samples were collected at various time points: urine, feces and
blood. Urine was collected at baseline, 9 weeks follow-up and 24 months follow-
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up on three consecutive days between 10.00 and 14.00 hours. S. haematobium egg
counts were obtained by filtration of 10 ml urine and was performed using 12 mm
Nucleopore filters (Costar, Cambridge). Intensity was expressed by number of eggs
per 10 ml urine. Feces were collected at baseline prior to PZQ treatment to assess
parasitic coinfection and egg counts by Kato-Katz technique was performed twice
on one stool sample. Egg counts/g feces of Hymenolepis nana, Trichuris,
Ancylostoma duodenale, Ascaris and Schistosoma mansoni were calculated from a
template of 41.7 mg feces by multiplying slide results with 24 as described
elsewhere [22]. Blood. 5 ml blood in EDTA tubes was drawn pre-treatment by
veni-puncture to detect for malaria parasites and IgG1- and IgG3-antibodies
against Plasmodium falciparum for assessment of exposure by ELISA; antigen
preparation and ELISA conditions are as described elsewhere [23]. Presence of
malaria parasites was determined by microscopy of thick and thin smears
performed by trained microscopists. Plasma was harvested and stored at −20 °C
and placed on dry ice for shipment to Cambridge for antibody analysis. Samples
were treated with 0.3% tributyl phosphate/1% tween for viral inactivation and
subsequent storage at −80 °C [20].
Ultrasonography (US) was performed pre-treatment, and 9-months and 2-years
post-treatment by two examiners for each participant using the consensus strategy
[24]. Both examiners had extensive field experience with US examinations and
followed WHO Niamey guidelines [25] using an Aloka SSD-500 3.5 MHz convex
sector scanner powered by a portable generator. For liver size and portal vein
diameter (PVD), the height adjustment included the linear and the quadratic term
of height. For spleen length, only the linear term was needed.
2.1. Data analysis
Data were analysed using Stata v.14 (StataCorp LP, Texas 77845 USA). Infection
status and intensity of S. haematobium infection were analysed in relation to
gender, village, ethnic group, age groups (generated as 5 classes with
approximately equal representation), treatment regimen, S. mansoni infection
and Plasmodium infection using logistic and negative binomial regression analysis
respectively. All factors were analysed individually and then jointly, followed by
manual elimination of non-significant factors based on p-value. The models were
specified as generalized linear models with a logit and log link function. Standard
errors were adjusted for clustering within households. All participants who
returned 1, 2 or 3 urine samples at any scheduled time (baseline, 9 weeks and 2
years post-treatment) were included in the analysis and the logn of number of urine
samples was used as an offset. Liver and spleen length in cm and portal vein
diameter (PVD) in mm were analysed as continuous variables using linear
regression as specified in a generalized linear model with a unit link function and
adjusting standard errors for possible clustering in households. Predictors were the
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same as for prevalence and intensity of infection and the principle of analysis was
the same. In addition, intensity of S. haematobium infection categories was added.
Since the recommended WHO categories of above 50 eggs per 10 ml urine or
below 50 eggs per 10 ml urine resulted in highly unbalanced size of groups we
chose three groups of positive egg counts with approximately equal sample size.
Negatives constituted the control group. Similarly, malaria antibody (IgG1, IgG3
and IgA) concentrations were categorized into 4 groups of equal sample sizes and
used as predictors of organ sizes. Only participants, who tested positive for S.
haematobium and took part in all 3 parasitological examinations, were included in
the treatment effect analysis. Intensity of S. haematobium infection at baseline or
during the follow-up surveys was included as predictor either as category (see
above) or as continuous variable (e.g. logn(x + 1)). Left liver lobe length, spleen
length and PVD were also assessed by scoring measurements as either normal,
mildly enlarged or severely enlarged [26]. In order to assess changes in these three
measures following treatment, we compared changes in measurements among
those who were scored as normal, mildly enlarged or severely enlarged at baseline.
Since size of left liver lobe, spleen and PVD are correlated with height [26] we
worked out this relationship at baseline using polynomial regression [27]. As
measurement of organ size at baseline we used the residual value. Assuming the
baseline relationship between organ measurement and height at baseline would still
be valid at the 9 months and 2 years follow-up, we worked out a predicted size
based on height at follow-up times. Height was only measured at baseline and at
the 2 years follow-up and height at 9 months was interpolated between baseline
and two years height measurements considering the average age-specific height-
growth rate as estimated from the height-age relationship at baseline (using
polynomial regression). The difference between the actual score and the predicted
mean (“residual”) was then a measure at the follow-up time. Change in organ size
was the “residual” at the follow-up time minus the residual at baseline. Changes in
morbidity (micro- and macro-haematuria and megaly of spleen, liver and PVD)
status (present, absent) between two surveys were analysed using McNemar chi-
square test (data not shown).
2.2. Compliance with ethical standards
The study received ethical approval from the Ethical Review Committee of the
National Institute for Research in Public Health, Mali (Decision 0002/INRSP/
DAP/SP- 2005). Study procedures were explained to participants prior to
enrolment and oral consent was obtained from adults and parents/guardians of
children prior to inclusion. Oral consent is deemed acceptable by the Malian
Ministry of Health due to cultural reasons and literacy rates within rural
populations.
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3. Results
Pre-treatment, a total of 122 people (30.4%) provided all three urine samples, 222
people (55.4%) provided two samples and 57 people (14.2%) only returned one. All
were included in the baseline analyses (Table 1). Overall prevalence of S.
haematobium infection was 79.8% and prevalence was and lowest in the 2–5 years
old (Table 1). Maximum intensity was 996 eggs per 10 ml urine (Table 1). When
compared to the 2–5 year group, participants between 16–28 years had a 3.6 times
higher odds of infection and participants in the 29–40 year group had a 1.86 times
higher odds of infection. Fecal samples were collected from 291 people revealing
S. mansoni/S. haematobium co-infection in 38 (13.1%). Hymenolepis nana was
found in 9 participants (3.1%) with an egg density range of 48–8632 eggs per gram
feces. Unidentified helminth eggs were found in four samples (1.4%).
Analysis of post-treatment parasitology exclusively contains participants complet-
ing all 3 parasitological examinations i.e. baseline, 9 weeks and 2 years (n = 157;
49.1%). A total of 25 people (15.9%) were still positive for S. haematobium eggs 9
weeks post-treatment. The final model of infection status at 9 weeks showed
significance in the quadratic term of baseline intensity, i.e. baseline intensity (b =
0.43, p not significant (p ns)) and baseline intensity squared (b = 1.20, p < 0.05).
In this model, females had lower odds of being S. haematobium positive compared
to males (b = 0.23, p <0.01; 95% CI 0.09–0.62) 9 weeks post-treatment and people
older than 5 years of age had increased odds of being infected than those younger
than 5 (b = 8.57, p < 0.05; 95% CI 1.03–70.9). Dual-dose treatment resulted in
borderline lower odds of persistent infection (b = 0.41, p = 0.05; 95% CI
0.17–1.00). After 2 years, the only significant predictor was intensity of infection
at baseline (b = 1.28, p < 0.05). Participants aged 16–40 years had lower odds of
infection than participants younger than 16 (b = 0.16, p < 0.001; 95% CI
0.07–0.37).
At 9 weeks, egg count predictors were the linear (b = 0.47, p ns) and quadratic (b =
1.25, p < 0.05) terms of logn baseline intensity of infection. Females had lower egg
counts than males (b = 0.06, p < 0.001; 95% CI 0.01–0.21) and participants older
than 5 years of age had higher egg counts than participants under age 5 (b = 85.26,
p < 0.001; 95% CI 11.66–623.42). Participants receiving dual-dose treatment had
egg-counts that were 30% of those who received single-dose treatment (b = 0.30, p
ns; 95% CI 0.05–1.68). The model, however, was over-dispersed and interpretation
should be done with caution.
Size of left liver lobe, spleen length and PVD were related to height. Predictors of
liver size adjusted for height were gender (females averaged 0.38 cm larger than
males) and high intensity of S. haematobium infection (Table 2). Liver
measurements were larger in people with high anti-Plasmodium IgG-values
[IgG1-values above 325 ug/ml (b = 0.40 cm, p < 0.01) and IgG3-values above
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Table 1. Prevalence and intensity of Schistosoma haematobium infections in people living in the Segou
District, Mali. Possible predictors of these variables were tested individually (uni-variable) and then jointly,
removing insignificant variables (multi-variable) using logistic and negative binomial regression,
respectively.
Prevalencea Intensity
Parameter N Proportion
infected.
Uni-vari-
able
Multi-vari-
able
(Geometric mean of [eggs/10 ml] +
1) − 1
Uni-varia-
bleb
Multi-varia-
bleb
Total
Over all 401 0.798 11.4 (996.3)
Age group
2–5 78 0.628 1.00 1.00 8.0 (903.7) 1.00 1.00
6–8 78 0.859 3.60** 3.50** 33.4 (996.3) 1.44 1.00
9–15 84 0.881 4.38*** 3.39** 16.5 (563.0) 0.78 1.00
16–28 78 0.859 3.60** 2.55 9.1 (600.0) 0.52 0.43***
29–40 83 0.759 1.86** 1.69 4.6 (266.0) 0.24*** 0.26***
Gender
Male 189 0.820 1.00 11.8 (996.3) 1.00
Female 212 0.778 0.77 11.1 (712.0) 0.76
Village
Kalabogou 216 0.704 1.00 1.00 6.0 (545.5) 1.00 1.00
Kaladagan 108 0.870 2.83*** 2.73*** 18.1 (996.3) 2.85*** 3.03***
Guenidaga 77 0.961 10.39** 8.80** 32.7 (903.7) 3.67*** 3.31***
Tribe
Bambara 205 0.727 1.00 6.8 (545.5) 1.00
Bozo 154 0.909 3.76*** 22.2 (903.7) 2.62***
Other 42 0.738 1.06 11.7 (996.3) 2.33
Treatment
Single 225 0.813 1.00 12.2 (996.3) 1.00
Double 176 0.778 0.81 10.5 (834.5) 1.19
S. mansoni
Negative 253 0.794 10.7 (996.3) 1.00
Positive 38 1.000 c 33.5 (834.5) 1.86*
S. haematobium
Negative 81 0.0 (0.0)
0.3–3.5 80 1.4 (3.7)
3.5–22.5 80 9.8 (23.0)
22.5–90.0 80 49.0 (92.5)
>90.0 80 234.5 (996.3)
(Continued)
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54.9 ug/ml (b = 0.35 cm, p < 0.05)]. Due to co-linearity between the two, only
IgG1-values over 325 ug/ml were retained in the multi-variable analysis, e.g.
gender (b = 0.38 cm, p < 0.01), S. haematobium intensity category 4 (b = 0.36 cm,
p < 0.01), S. haematobium intensity category 5 (b = 0.41 cm, p < 0.05) and IgG1-
values over 325 ug/ml (b = 0.33 cm, p < 0.05).
Spleen length was linearly correlated with height. Females had relatively smaller
spleens than males when keeping height constant (Table 2). Higher scores were
seen in S. mansoni positives compared to negatives (Table 2). When adjusting for
height, spleen size increased with level of anti-malarial IgG1 (< 95 ug/ml
(reference category), 95–184 ug/ml (b = 0.36 cm, p ns), 185–324 ug/ml (b = 0.51
cm, p < 0.05), and 325–990 ug/ml (b = 1.16 cm, p < 0.001) and similarly for IGg3
levels, (< 8.8 ug/ml (reference category), 8.9–28.3 ug/ml (b = 0.14 cm, p ns),
28.6–54.8 ug/ml (b = 0.37 cm, p ns) and 54.9–1427 ug/ml (b = 1.16 cm, p <
0.01)). Adding these levels to the final model (Table 2) resulted in this model:
height (b = 0.04 cm, p < 0.001); gender (b = -0.58, p < 0.01); S. haematobium
intensity category 2: (0.3–3.5 eggs/g feces; b = 1.12, p < 0.001), S. haematobium
intensity category 3: (3.5–22.5 eggs/g feces; b = 0.65, p<0.05), S. haematobium
intensity category 4: (22.5–90.0 eggs/g feces; b = 0.73, p<0.01); S. haematobium
intensity category 5: (>90 eggs/g feces; b = 0.65, p < 0.05); IgG1 category 4:
(325–990 ug/ml; b = 0.75, p< 0.05); and IgG3 category 4: (54.9–1427.3 ug/ml; b =
0.53, p< 0.05). Portal vein diameter was larger in males than in females and in the 2
older age groups than in the younger groups. No other predictors were significant.
Liver size was classed as normal in 46.9% of participants (N = 399), while 44.1%
had moderately enlarged livers and 9.0% had severely enlarged livers. Spleen size
was normal in 42.6% of participants (N = 398) while 41.4% had moderate and
Table 1. (Continued)
Prevalencea Intensity
Parameter N Proportion
infected.
Uni-vari-
able
Multi-vari-
able
(Geometric mean of [eggs/10 ml] +
1) − 1
Uni-varia-
bleb
Multi-varia-
bleb
Malaria
Negative 70 0.757 1.00 7.5 (766.7) 1.00
Positive 284 0.856 1.90 14.0 (996.3) 1.46
a coefficients are odds ratios.
b coefficients are count ratios.
c All 38 S. mansoni cases are also positive for S. haematobium; regression coefficient not estimated.
* denotes p-values < 0.05.
** denotes p-values < 0.01.
*** denotes p-values < 0.001.
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Table 2. Association between size of left liver lobe, spleen length and peri-portal vein diameter and various
potential predictors including Schistosoma haematobium infection intensity in people living in the Segou
District, Mali February 2007. The factors were tested individually (“Uni-variable”) adjusting for height and
possibly height squared and jointly (Multi-variable) using linear regression.
Parameter N Left liver lobe (cm) Spleen length (cm) PVD (cm)
N = 399; Range: 4.3–10.7 N = 398; Range: 5.4–25.0 N = 398; Range; 5.0–17.0
Uni-variable Multi-variable Uni-variable Multi-variable Uni-variable Multi-variable
Height (cm) 399 0.07***,a 0.07* 0.04***,a 0.04*** −0.06a −0.01
Height2 (cm2) 399 0.00**,a 0.00 0.00***,a 0.00
age group
2–5 78 0.00 0.00 0.00 0.00
6–8 78 0.24 0.01 −0.35 0.00
9–15 84 0.34 0.07 −0.26 0.00
16–28 78 0.41 −0.07 0.07 0.57*
29–40 83 0.35 −0.64 0.55 1.05***
Gender
Male 189 0.00 0.00 0.00 0.00 0.00 0.00
Female 212 0.38** 0.38** −0.56** −0.63** −0.28 −0.40*
S. mansoni
Negative 253 0.00 0.00 0.00
Positive 38 0.18 0.83** 0.17
S. haematobium
Negative 81 0.00 0.00 0.00 0.00
0.3–3.5 80 0.05 0.00 0.97*** 0.59*
3.5–22.5 80 0.18 0.00 0.65* 0.18
22.5–90.0 80 0.44** 0.36** 0.71** 0.35
>90.0 80 0.38** 0.41* 0.67** 0.47
Malaria
Negative 70 0.00 0.00 0.00
Positive 284 0.09 0.46 −0.33
Ig1
<95 89 0.00 0.00 0.00 0.00
95–184 89 0.25 0.00 0.36 −0.16
185–324 89 0.20 0.00 0.51* 0.03
325–990 89 0.56** 0.33* 1.16*** 0.72* 0.32
(Continued)
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16.0% had severe splenomegaly. PVD was normal in 65.8% of participants (N =
398), while 30.2% had moderately and 4.0% were severely enlarged PVD.
A total of 81 participants were S. haematobium infection negative at baseline and
excluded from the analysis of post-treatment organomegaly. Of the remaining 320
participants 236 (73.8%) were examined after 9 months. A total of 178 people
(55.6%) were examined after two years.
Post-treatment data on liver-, spleen- and portal vein diameter-enlargement is
presented in Table 3. Overall prevalence of organomegaly showed little effect from
treatment because several cases reverted from having organomegaly to being
normal and vice versa. This was true in all age groups (Table 3). Significant
differences were seen when changes in organ size for height-residuals were
analysed by organ enlargement classifications at baseline. Participants with
normal-sized livers at baseline had averagely 0.53 cm larger livers than observed at
baseline (p < 0.001), while liver size was smaller after treatment in those with
moderately or severely enlarged livers at baseline: −0.23 (p < 0.05) and −0.58 (p
< 0.01), respectively (Fig. 1). Significant predictors of these differences were
baseline liver size and age group with the 3 older age groups having greater
regression of their liver size on average (b = -0.43, p < 0.01; 95% CI −0.71–0.16)
than the two younger age-groups. Participants with moderately enlarged livers (b =
-0.94 cm, p < 0.001; 95% CI −1.19–0.69) and severely enlarged livers (b = -1.31
Table 2. (Continued)
Parameter N Left liver lobe (cm) Spleen length (cm) PVD (cm)
N = 399; Range: 4.3–10.7 N = 398; Range: 5.4–25.0 N = 398; Range; 5.0–17.0
Uni-variable Multi-variable Uni-variable Multi-variable Uni-variable Multi-variable
Ig3
<8.8 89 0.00 0.00 0.00
8.9–28.3 89 −0.22 0.14 −0.29
28.6–54.8 89 0.08 0.37 0.24
54.9–1427.3 89 0.31 0.98** 0.60* 0.08
IgA
<8.8 89 0.00 0.00 0.00
8.9–28.3 89 0.06 0.24 0.02
28.6–54.8 89 0.00 0.35 0.11
54.9–1427.3 89 0.36 0.23 0.43
a Coefficients are for the height and height squared as the sole predictor(s).
* denotes p-values < 0.05.
** denotes p-values < 0.01.
*** denotes p-values < 0.001.
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cm, p < 0.001; 95% CI −1.65–0.98) had lower scores than those with normal-sized
livers (Fig. 1). Analysis of the original measurements without height adjustment
showed the same trends (analysis not shown). Changes in liver size from 9 months
to 2 years were small and not significantly different from zero in any of the
3 groups.
Spleen size in participants with normal spleens were on average 0.13 cm larger
after treatment than observed at baseline (p ns), while in those with moderately or
severely enlarged spleens, differences were lower, e.g. −0.72 cm (p < 0.001) and
−1.73 cm (p < 0.001), respectively. The only significant predictor of changes in
residuals was baseline spleen-size. i.e. for moderately enlarged (b = -0.86 cm,
p < 0.001; 95% CI −1.33–0.39) and severely enlarged (b = -1.87 cm, p < 0.001;
95% CI −2.52–1.22). Changes in spleen size from 9 months to 2 years were small
and not significantly different from zero in those who scored normal at baseline.
Those with moderately enlarged and severely enlarged spleens at baseline had
increased spleen size from 9 months to 2 years i.e. 0.61 cm, p ns; 95% CI
−0.23–1.46 and 0.43, 95% CL: 0.04–0.82; p < 0.05, respectively.
PVD scores in participants with normal measurements at baseline were on average
0.16 cm larger at 9 months follow-up (p ns), while those with moderate or severe
Table 3. Effect of treatment on prevalence and intensity of Schistosoma
haematobium infections and prevalence of various morbidity indicators in people
living in the Segou District, Mali from February 2007 (Baseline) to February 2009
(two years).
n Baseline N 9 weeks n 9 months n 2 years
Prevalence (%) 157 100.0 157 15.9 157 70.7
Intensity (eggs 10 ml−1) 157 21.98 157 0.22 157 5.87
Micro-haematuria (%) 144 75.0 152 18.4 155 50.3
Macro-haematuria (%) 144 47.9 153 17.6 155 20.0
Anemia (%) 148 38.5 146 21.9 157 59.2
Bladder pathology (%) 155 11.6 139 2.9 155 27.1
Upper urinary tract (%) 155 13.5 139 7.2 155 8.4
Moderate hepatomegaly (%) 157 51.0 157 55.4 157 50.6
Severe hepatomegaly (%) 157 8.9 157 13.4 157 6.3
Moderate splenomegaly (%) 157 54.8 157 54.1 157 45.6
Severe splenomegaly (%) 157 16.6 157 15.3 157 10.8
Moderately enlarged PVD (%) 157 35.0 157 34.4 157 19.0
Severely enlarged PVD (%) 157 3.2 157 10.2 157 1.3
Mean global score 155 2.02 139 0.57 155 1.56
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Fig. 1. Changes in residuals (residual at the end of period minus residual at beginning of period) in liver
(A) and spleen size (B) and portal vein diameter in people who a baseline were scored as normal,
moderately (2sd-4sd) and severely enlarged (>4sd) based on the WHO classification.
Article No~e00440
12 http://dx.doi.org/10.1016/j.heliyon.2017.e00440
2405-8440/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
PVD enlargements at baseline had lower measurements at 9 months after
treatment, i.e. −1.08 mm (p < 0.001) and −2.46 mm (p < 0.05: n = 3),
respectively. Significant predictors were PVD size at baseline and age group with
the three older age groups averaging lower scores (b = -0.94 mm, p < 0.001; 95CI
−1.47–0.42) than the two younger age groups. In the same model, participants with
moderately enlarged PVD and severely enlarged PVD at baseline had lower scores
than those with normal PVDs. Changes in residuals from 9 months to 2 years were
small and not significantly different from zero in any of the three groups.
4. Discussion
The current study conducted an ultrasonographic assessment of S. haematobium-
related morbidity across a wide age range to detect possible organomegaly and
determine the effect of two different PZQ-treatment strategies on the resolution of
acute and chronic morbidity.
Our study confirmed previous findings that S. haematobium prevalence and
infection intensity are more pronounced in the 9–15 year age group [12]. Among
adults, men were more heavily infected than women and differences between
villages confirm previous findings of occupational hazards for communities whose
livelihood is fishing. Adding a second dose of PZQ showed a short-term benefit of
lower rate of persistent infection, or acute symptoms at 9 weeks in the dual-dose
treatment group, but long-term benefits for chronic lesions were not observed.
Given the highly endemic environment, rapid reinfection is probable; therefore,
timing of a second dose must account for reinfection and the life cycle of the
parasite as young parasites are not killed and serve as a reservoir for persistent
infection [28]. The stage from penetration of the human skin to the first passage of
eggs via urine takes approximately 70 days [29]. The number of immature worms
at any given time is highly dependent on transmission and the ideal timing of the
second dose of PZQ is variable. The second dose in our study was administered
after two weeks to comply with similar studies from Kenya and Uganda [30] and to
secure adherence in the community.
Our study indicated an interesting reduction in the occurrence of reinfection in the
16–40 years age group, which supports the argument of including this population
in treatment programs to reduce individual pathology, and also assist in breaking
the transmission cycle and support resistance against possible HIV infection in this
highly exposed population. Although not yet used PZQ has proven safe in small
children. Studies have shown that even very young children are at risk of
developing chronic lesions, which will later develop into chronic genital ulcers in
adolescence and thereby enhance the risk of HIV acquisition [2]. This excluded
group also plays a role in maintaining the transmission cycle of schistosomiasis
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and there could be an untapped chance of reducing transmission by including the
youngest and oldest in MDA programs in the future.
In S. mansoni infected individuals, chronic hepato-splenomegaly is common and
caused by egg-induced inflammation and lack of immunologic regulation [31].
Gross peri-portal fibrosis, portal hypertension, enlarged PVD, ascites and collateral
vessels occur after long-term untreated exposure [32]. One study suggests a
reduced risk of hepatomegaly if co-infected with S. mansoni and S. haematobium
[33]. We found high prevalences of organomegaly in the community at individual
levels, but pooling the overall measurements does not explain the actual dynamics
and at a community level treatment does not seem to have significant impact on
resolution of organomegaly because the normalized organs are replaced by
diseased organs in the analysis (Table 3, Fig. 1). In the current study co-infection
with S. mansoni occurred in few participants (13.1%), which is unlikely to explain
the extension of organomegaly observed in the community. A different study from
Molodo, Mali (Belonging to the Niono District, Segou region, which is an
irrigation area) detects high prevalences of S. mansoni, but the current study has
been conducted in the District of Segou, along the river Niger (Segou Region),
which holds a totally different ecologic setting regarding snail habitat [22]. Ectopic
abundance of S. haematobium infection, defined as eggs or worms trapped outside
the classical genitourinary organ location, is thought to be responsible for
hepatomegaly in S. haematobium infected individuals [33, 34]. In the current
study, the most profound organ recoveries are seen during the first follow-up
period after treatment and prior to the occurrence of reinfection. The demonstrated
hepato-splenomegaly was most profound in participants below 6 years of age,
which is also when immunity to malaria has not yet fully developed and malaria as
a contribution factor to organomegaly must be taken into account. A previous study
on the contribution of malaria to organomegaly in a S. mansoni endemic area
concluded that schistosomiasis was the single most attributable factor and malaria
played no role in hepatomegaly [24]. An opposing study found more serious
hepato-splenomegaly in chronic malaria exposed augmented by concomitant S.
mansoni infection and demonstrated pro-inflammatory mechanisms behind the
additive effect [35]. Nevertheless, the recovery from organomegaly after PZQ in
the current study cannot be explained by concomitant malaria-infection, as
Plasmodium falciparum is refractive to PZQ treatment [36]. Distinguishing
between organomegaly caused by malaria and schistosomiasis is a problem due to
the geographic and seasonal overlap of the two diseases [37]. Our study
demonstrated a novel finding of an association between PVD enlargement and S.
haematobium infection intensity, which cannot be explained by malaria co-
infection, but conclusively one cannot rule out the role of chronic exposure to P.
falciparum on hepatomegaly and more research is needed to confirm the role of S.
haematobium in development of organomegaly. Using ultrasound, PVD is an
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easily accessible structure to measure and a combination of the three organ-specific
observations combined as an aggregated disease-score could provide a new tool for
detection of schistosomiasis-related pathology.
As with all clinical studies this study has limitations. The current results correlate
well with classical morbidity measures, such as intensity of infection and
hematuria, but early stages of disease are not visualized by ultrasonography. One
important challenge was lack of information regarding potential confounding
diseases. Hepato-splenomegaly in sub-Saharan Africa is attributable to many
aetiologies, such as leishmaniasis, typhoid fever, brucellosis, HIV, TB, hepatocel-
lular cancers and chronic viral Hepatitis B and C. Additionally, 28% of individuals
with pyrexia has been shown to have peri-portal thickening [37]. In the current
study none of the included participants had fever, and leucocyte counts and blood
pressure measurements point away from any of those chronic diseases in the
population although a recent study from Mali reports a Hepatitis-B prevalence of
10–18% in adults [38]. According to the World Bank HIV-prevalence in Mali in
2015 is 1.3% in the 15–49 year age group. S. mansoni was found in 38 of 291
participants (13%) in our study. Almost no reinfection with S. mansoni was
detected after treatment, suggesting that the initial S. mansoni infections were
imported cases of migrating fishermen.
In conclusion we find that S. haematobium is a plausible cause of organomegaly in
this endemic area and recommend repetition of treatment within 2 years to prevent
long-term morbidity [6]. Dual-dose treatment does not reduce long-term morbidity
more than single-dose regimens, mainly due to high efficiency of the first dose and
unavoidable reinfection. With the global aim of eliminating schistosomiasis, MDA
programs must step up and face the neglected gap of excluded populations to
reduce long-term morbidity and schistosomiasis transmission and to protect against
the HIV-epidemic in Africa securing the best deployment of available economic
resources. Further studies, limiting the confounders of the current one, are needed
to confirm the findings and extend the investigations of possible S. haematobium
related organomegaly.
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